1. ^*Institute of Human Genetics, University Erlangen-Nuremberg, Nuremberg, Germany
2. ^†Department of Dermatology, University of Münster, Münster, Germany
3. ^‡Department of Internal Medicine III (Rheumatology), University Erlangen-Nuremberg, Nuremberg, Germany
4. ^§Psoriasis Rehabilitation Hospital, Bad Bentheim, Germany
5. ^¶Rheumatologische Schwerpunktpraxis, Erlangen, Germany
6. ^#Institute for Transfusion Medicine, University Clinics of Münster, Münster, Germany
7. ^**TOMESA Clinics, Bad Salzschlirf, Germany
8. ††Institute of Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany

Correspondence: André Reis, Institute of Human Genetics, University of Erlangen-Nuremberg, Schwabachanlage 10, 91054 Erlangen, Germany. Email: areis@humgenet.uni-erlangen.de

Received 30 April 2004; Revised 8 September 2004; Accepted 28 September 2004; Published online 21 December 2004.

Abstract

A DNA variant, rs734232, altering a RUNX1 binding site was recently reported as susceptibility allele at PSORS2 (17q25) in cohorts of psoriasis patients from the US. A testing of this variant in psoriasis patients from Germany did not confirm this association in 300 trios nor in two case–control studies with 281 patients with psoriasis vulgaris and 375 patients with psoriatic arthritis, respectively. These results fail to support rs734232 as a psoriasis susceptibility factor in German psoriasis patients.